Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
End points in advanced colon cancer clinical trials: a review and proposal.
Allegra C, Blanke C, Buyse M, Goldberg R, Grothey A, Meropol NJ, Saltz L, Venook A, Yothers G, Sargent D. Allegra C, et al. Among authors: blanke c. J Clin Oncol. 2007 Aug 20;25(24):3572-5. doi: 10.1200/JCO.2007.12.1368. J Clin Oncol. 2007. PMID: 17704403 Review. No abstract available.
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.
Sargent DJ, Wieand HS, Haller DG, Gray R, Benedetti JK, Buyse M, Labianca R, Seitz JF, O'Callaghan CJ, Francini G, Grothey A, O'Connell M, Catalano PJ, Blanke CD, Kerr D, Green E, Wolmark N, Andre T, Goldberg RM, De Gramont A. Sargent DJ, et al. J Clin Oncol. 2005 Dec 1;23(34):8664-70. doi: 10.1200/JCO.2005.01.6071. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260700
The continuum of care: a paradigm for the management of metastatic colorectal cancer.
Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB 3rd, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. Goldberg RM, et al. Among authors: blanke cd. Oncologist. 2007 Jan;12(1):38-50. doi: 10.1634/theoncologist.12-1-38. Oncologist. 2007. PMID: 17227899 Free article. Review.
Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
Venook AP, Blanke CD, Niedzwiecki D, Lenz HJ, Taylor JR, Hollis DR, Sutherland S, Goldberg RM. Venook AP, et al. Clin Colorectal Cancer. 2007 May;6(7):536-8. doi: 10.3816/CCC.2007.n.021. Clin Colorectal Cancer. 2007. PMID: 17553204 Clinical Trial. No abstract available.
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.
de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. de Gramont A, et al. Among authors: blanke cd. J Clin Oncol. 2010 Jan 20;28(3):460-5. doi: 10.1200/JCO.2009.23.1407. Epub 2009 Dec 14. J Clin Oncol. 2010. PMID: 20008641 Free PMC article.
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M, de Gramont A; Adjuvant Colon Cancer End-points (ACCENT) Group. Sargent D, et al. Eur J Cancer. 2011 May;47(7):990-6. doi: 10.1016/j.ejca.2010.12.015. Epub 2011 Jan 21. Eur J Cancer. 2011. PMID: 21257306 Free PMC article.
231 results